<DOC>
	<DOCNO>NCT01097668</DOCNO>
	<brief_summary>Phase 1 study ass safety biological activity ATX-MS-1467 patient relapse form multiple sclerosis . This open label upward dose titration involve injection 9 occasion , two week apart . After dose complete 22 week follow period . Blood sample draw throughout study monitor safety body 's response injection MRI scan perform several occasion follow course multiple sclerosis trial .</brief_summary>
	<brief_title>ATX-MS-1467 Patients With Relapsing Forms Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>1 . Patients definite relapse multiple sclerosis disease define McDonald criterion ( McDonald et al. , 2001 2005 ) assess neurologist . 2 . HLA DRB1*15 positive . 3 . High baseline level Tcell proliferation response myelin basic protein , define &gt; 1000 cpm &gt; 3 stimulation index compare background . 4 . Disease duration equal le 10 year ( first clinical event ) . 5 . At least one document relapse previous 12 month two relapse within previous 24 month prior screen . 6 . Must clinically stable improve neurological state 28 day precede Screening . 7 . EDSS score &lt; 5.5 . 1 . Subjects treat Î²interferon , plasma exchange , intravenous gamma globulin within 3 month prior Study Day 1 2 . Subjects treat glatiramer acetate time past 3 . Subjects treat parenteral steroid adrenocorticotropic hormone within 3 month day prior Study Day 1 4 . Prior treatment : cytotoxic agent ( include limit cladribine , mitoxantrone , cyclophosphamide , azathioprine , methotrexate ) , fingolimod , laquinimod , teriflunomide , total lymphoid irradiation , stem cell bone marrow transplantation , monoclonal antibody therapy ( include natalizumab , daclizumab , alemtuzumab ) 5 . Prior use disease relate Tcell vaccine peptidetolerising agent treat MS 6 . Use investigational drug experimental procedure within 6 month prior Study Day 1 include cytokine anticytokine therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Immunomodulation</keyword>
	<keyword>Phase 1</keyword>
</DOC>